A Clinical Trial to Evaluate the Safety and Efficacy of Descovy for PrEP in Cisgender Women and Adolescent Females Weighing At Least 35 kg and Who are at Risk of Sexually Acquired HIV-1 Infection in Africa
Latest Information Update: 13 Nov 2019
At a glance
- Drugs Emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
Most Recent Events
- 13 Nov 2019 New trial record